Biotech · Public company · Pittsburgh, PA, US
Krystal Biotech, Inc.
Ticker KRYS · SEC CIK 0001711279
Track this companyFree. Adds Krystal Biotech, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials1711 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline18
- KB803Phase 3 · Dystrophic Epidermolysis BullosaClinicalTrials.gov · fetched Nov 12, 2026
- Open Label Topical Beremagene Geperpavec (B-VEC)Phase 3 · Dystrophic Epidermolysis BullosaClinicalTrials.gov · fetched Nov 12, 2026
- Topical Beremagene GeperpavecPhase 3 · Dystrophic Epidermolysis BullosaClinicalTrials.gov · fetched Nov 12, 2026
- ChemotherapyPhase 2 · Lung Cancer, Non-small CellClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 2 · Lung Cancer, Non-small CellClinicalTrials.gov · fetched Nov 12, 2026
- KB105Phase 2 · Autosomal Recessive IchthyosisClinicalTrials.gov · fetched Nov 12, 2026
- KB105Phase 2 · TGM-1 Related Autosomal Recessive Congenital IchthyosisClinicalTrials.gov · fetched Nov 12, 2026
- KB304Phase 2 · Wrinkles in DecolletageClinicalTrials.gov · fetched Nov 12, 2026
- KB707Phase 2 · Lung Cancer, Non-small CellClinicalTrials.gov · fetched Nov 12, 2026
- KB707Phase 2 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- KB801Phase 2 · Neurotrophic KeratitisClinicalTrials.gov · fetched Nov 12, 2026
- KEYTRUDA ®( Pembrolizumab)Phase 2 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- OpdualagPhase 2 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA®)Phase 2 · Lung Cancer, Non-small CellClinicalTrials.gov · fetched Nov 12, 2026
- KB111Phase 1 · Hailey Hailey DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- KB301Phase 1 · Skin RoughnessClinicalTrials.gov · fetched Nov 12, 2026
- KB407 (Nebulization)Phase 1 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- KB408 (Nebulization)Phase 1 · Alpha 1-Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials17
- A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey DiseaseEARLY_PHASE1 · RECRUITING · started May 6, 2026ClinicalTrials.gov NCT07717346 · fetched Nov 12, 2026
- A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic KeratitisPHASE1_PHASE2 · RECRUITING · started Jul 7, 2025ClinicalTrials.gov NCT06999733 · fetched Nov 12, 2026
- A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaPHASE3 · RECRUITING · started Jun 20, 2025ClinicalTrials.gov NCT07016750 · fetched Nov 12, 2026
- A Study Assessing KB304 for the Treatment of Wrinkles in WomenPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 20, 2024ClinicalTrials.gov NCT06724900 · fetched Nov 12, 2026
- A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)RECRUITING · started Aug 2, 2024ClinicalTrials.gov NCT06563414 · fetched Nov 12, 2026
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsPHASE1_PHASE2 · RECRUITING · started Apr 17, 2024ClinicalTrials.gov NCT06228326 · fetched Nov 12, 2026
- A Study of KB408 for the Treatment of Alpha-1 Antitrypsin DeficiencyPHASE1 · RECRUITING · started Feb 15, 2024ClinicalTrials.gov NCT06049082 · fetched Nov 12, 2026
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsPHASE1_PHASE2 · RECRUITING · started Oct 31, 2023ClinicalTrials.gov NCT05970497 · fetched Nov 12, 2026
- A Study Assessing KB407 for the Treatment of Cystic FibrosisPHASE1 · RECRUITING · started Jun 30, 2023ClinicalTrials.gov NCT05504837 · fetched Nov 12, 2026
- Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)PHASE2 · UNKNOWN · started Mar 1, 2023ClinicalTrials.gov NCT05735158 · fetched Nov 12, 2026
- Long-Term Follow-up ProtocolRECRUITING · started May 25, 2021ClinicalTrials.gov NCT04917887 · fetched Nov 12, 2026
- A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaPHASE3 · COMPLETED · started May 25, 2021ClinicalTrials.gov NCT04917874 · fetched Nov 12, 2026
- A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin DepressionsPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 7, 2020ClinicalTrials.gov NCT04540900 · fetched Nov 12, 2026
- Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEBPHASE3 · COMPLETED · started Aug 17, 2020ClinicalTrials.gov NCT04491604 · fetched Nov 12, 2026
- The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)WITHDRAWN · started Jan 1, 2020ClinicalTrials.gov NCT04214002 · fetched Nov 12, 2026
- Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)PHASE1_PHASE2 · UNKNOWN · started Aug 27, 2019ClinicalTrials.gov NCT04047732 · fetched Nov 12, 2026
- A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB PatientsPHASE1_PHASE2 · COMPLETED · started May 6, 2018ClinicalTrials.gov NCT03536143 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 17, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026